肺癌组织PTPN6、PAX8表达水平及其与患者预后的关系-东南大学学报医学版

肺癌组织PTPN6、PAX8表达水平及其与患者预后的关系

单位：河南黄河科技学院附属医院呼吸内科, 河南郑州 450000

分类号：R734.2

出版年·卷·期（页码）：2024·43·第五期（717-723）

摘要：

目的: 探讨蛋白质酪氨酸磷酸酶非受体型6(PTPN6)、配对盒基因8抗体(PAX8)在肺癌组织中表达水平及其与患者预后的关系。方法: 选取本院2019年1月至2021年1月收治的86例肺癌患者,在术中收集癌组织和癌旁组织。采用实时荧光定量PCR(qRT-PCR)检测组织中PTPN6、PAX8的mRNA表达,采用免疫组化法检测组织中PTPN6、PAX8的蛋白表达。结果: PTPN6 mRNA在肺癌组织中的表达低于癌旁组织(P＜0.05);PAX8 mRNA在肺癌组织中的表达高于癌旁组织(P＜0.05);肺癌组织中PTPN6蛋白阳性表达的患者3年生存率高于阴性表达者(P＜0.05);PAX8蛋白阳性表达的患者3年生存率低于阴性表达者(P＜0.05);淋巴结转移、肿瘤直径＞3.0 cm、低分化、TNM分期为Ⅲ~Ⅳ期、PTPN6阴性表达、PAX8阳性表达为影响肺癌患者预后的危险因素(P＜0.05)。结论: 肺癌组织PTPN6表达水平下降,PAX8表达水平上升,可作为评估患者预后的指标。

Objective: To explore the expression levels of protein tyrosine phosphatase non-receptor type 6(PTPN6) and paired box gene 8(PAX8) in lung cancer tissue and their relationship with prognosis. Methods: A total of 86 lung cancer patients admitted to our hospital from January 2019 to January 2021 were collected, and their cancer tissues and adjacent tissues were collected during surgery. The mRNA expression of PTPN6 and PAX8 in the two tissues was detected by real-time fluorescence quantitative PCR(qRT-PCR), and the protein expression of PTPN6 and PAX8 in the two tissues was detected by immunohistochemistry. Results: Significantly reduced levels of PTPN6 mRNA expression were observed in lung cancer tissues compared to the adjacent tissues(P＜0.05), while a marked increase was noted for PAX8 mRNA expression in the same comparison(P＜0.05). The 3-year survival rate of patients with PTPN6 protein positive expression in lung cancer tissue was higher than that of patients with negative expression(P＜0.05). The 3-year survival rate of patients with positive expression of PAX8 protein in lung cancer tissue was lower than that of patients with negative expression(P＜0.05). Lymph node metastasis, tumor diameter＞3.0 cm, low differentiation, TNM stage Ⅲ-Ⅳ, negative expression of PTPN6, and positive expression of PAX8 were risk factors affecting the prognosis of lung cancer patients(P＜0.05). Conclusion: The expression level of PTPN6 decreases in lung cancer tissue, while the expression level of PAX8 increases, and can be used as indicators for evaluating prognosis.

参考文献：

[1] SCHABATH M B,COTE M L.Cancer progress and priorities:lung cancer[J].Cancer Epidemiol Biomarkers Prev,2019,28(10):1563-1579.
[2] FASSNACHT M,JOHANSSEN S,QUINKLER M,et al.Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma:proposal for a Revised TNM Classification[J].Cancer,2009,115(2):243-250.
[3] LIU C Y,SU J C,HUANG T T,et al.Sorafenib analogue SC-60 induces apoptosis through the SHP-1/STAT3 pathway and enhances docetaxel cytotoxicity in triple-negative breast cancer cells[J].Mol Oncol,2017,11(3):266-279.
[4] WEN L Z,DING K,WANG Z R,et al.SHP-1 acts as a tumor suppressor in hepatocarcinogenesis and HCC progression[J].Cancer Res,2018,78(16):4680-4691.
[5] TAO T,YANG X,ZHENG J,et al.PDZK1 inhibits the development and progression of renal cell carcinoma by suppression of SHP-1 phosphorylation[J].Oncogene,2017,36(44):6119-6131.
[6] HUANG Z,CAI Y,YANG C,et al.Knockdown of RNF6 inhibits gastric cancer cell growth by suppressing STAT3 signaling[J].Onco Targets Ther,2018,11(1):6579-6587.
[7] ARAKAWA T,FUKUDA S,HIRATA T,et al.PAX8:a highly sensitive marker for the glands in extragenital endometriosis[J].Reprod Sci,2020,27(8):1580-1586.
[8] HU S,GAN H,YANG F.Significance analysis of PAX8 expression in endometrial carcinoma[J].Medicine(Baltimore),2022,101(42):217-226.
[9] XU L,SU Z,XIE B.Diagnostic value of conventional tumormarkers in young patients with pulmonary nodules[J].J Clin Lab Anal,2021,35(9):23912-23917.
[10] HAN Y,ZHANG J,PANG Y,et al.The role of Src homology region 2 domain-containing phosphatase-1 hypermethylation in the classification of patients with myelodysplastic syndromes and its association with signal transducer and activator of transcription 3 phosphorylation in skm-1 cells[J].J Int Med Res,2021,49(3):721-732.
[11] KHOUILI S C,COOK E C L,HERNÁNDEZ-GARCÍA E,et al.SHP-1 regulates antigen cross-presentation and is exploited by leishmania to evade immunity[J].Cell Rep,2020,33(9):584-593.
[12] ALBORZIAN DEH SHEIKH A,AKATSU C,ABDU-ALLAH H H M,et al.The protein tyrosine phosphatase SHP-1(PTPN6) but not CD45(PTPRC) is essential for the ligand-mediated regulation of CD22 in BCR-ligated B cells[J].J Immunol,2021,206(11):2544-2551.
[13] MYERS D R,ABRAM C L,WILDES D,et al.Shp1 loss enhances macrophage effector function and promotes anti-tumor immunity[J].Front Immunol,2020,11(1):1782-1791.
[14] LIU G,ZHANG Y,HUANG Y,et al.PTPN6-EGFR protein complex:a novel target for colon cancer metastasis[J].J Oncol,2022,21(3):2144-2153.
[15] LIM S,LEE K W,KIM J Y,et al.Consideration of SHP-1 as a molecular target for tumor therapy[J].Int J Mol Sci,2023,25(1):331-339.
[16] TONG H,LIU X,LI T,et al.MACC1-AS1 promotes hepatocellular carcinoma cell invasion and proliferation by regulating PAX8[J].Aging(Albany NY),2020,12(1):70-79.
[17] BIE L Y,LI N,DENG W Y,et al.Evaluation of PAX8 expression promotes the proliferation of stomach cancer cells[J].BMC Mol Cell Biol,2021,22(1):61-71.
[18] RODGERS L H,OH E,YOUNG A N,et al.Loss of PAX8 in high-grade serous ovarian cancer reduces cell survival despite unique modes of action in the fallopian tube and ovarian surface epithelium[J].Oncotarget,2016,7(22):32785-32795.
[19] ADLER E K,CORONA R I,LEE J M,et al.The PAX8 cistrome in epithelial ovarian cancer[J].Oncotarget,2017,8(65):108316-108332.
[20] DE CRISTOFARO T,DI PALMA T,SORIANO A A,et al.Candidate genes and pathways downstream of PAX8 involved in ovarian high-grade serous carcinoma[J].Oncotarget,2016,7(27):41929-41947.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录